Curcumin as potential therapeutic natural product: a nanobiotechnological perspective

Journal of Pharmacy and Pharmacology

Volumn 68, Issue 12, 2016, Pages 1481-1500

  Shome, Soumitra ^a,b   Talukdar, Anupam Das ^b   Choudhury, Manabendra Dutta ^b   Bhattacharya, Mrinal Kanti ^a   Upadhyaya, Hrishikesh ^c  

^a KARIMGANJ COLLEGE   (India)

^b ASSAM UNIVERSITY   (India)

^c Department of Molecular Biology and Biotechnology   (India)

Author keywords

curcumin; nanocomposite formulations; nanocurcumin; theraputic potential

Indexed keywords

1 VINYL 2 PYRROLIDINONE; CURCUMIN; CYCLODEXTRIN; DENDRIMER; GRAPHENE OXIDE; LIPOSOME; MACROGOL; POLY(N ISOPROPYLACRYLAMIDE); POLYGLACTIN; QUANTUM DOT; SOLID LIPID NANOPARTICLE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; ZINC OXIDE NANOPARTICLE; DRUG CARRIER; LACTIC ACID; LIPID; METAL NANOPARTICLE; OXIDE; PLANT EXTRACT; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANTIBACTERIAL ACTIVITY; ANTIDIABETIC ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; BURN; DERMATITIS; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC FOOT; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG SOLUBILITY; DRUG STRUCTURE; ECZEMA; ENCAPSULATION; HUMAN; HYPERTENSION; INTERNALIZATION; MALIGNANT NEOPLASTIC DISEASE; MICELLE; MINIMUM INHIBITORY CONCENTRATION; NANOBIOTECHNOLOGY; NONHUMAN; PSORIASIS; REVIEW; SCLERODERMA; SKIN INJURY; ANIMAL; BIOAVAILABILITY; CHEMISTRY; DRUG FORMULATION; NANOTECHNOLOGY; ORAL DRUG ADMINISTRATION; PHARMACEUTICS; PROCEDURES; SOLUBILITY;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CURCUMIN; DRUG CARRIERS; DRUG COMPOUNDING; HUMANS; LACTIC ACID; LIPIDS; METAL NANOPARTICLES; NANOTECHNOLOGY; OXIDES; PLANT EXTRACTS; POLYGLYCOLIC ACID; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 84991704675     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12611     Document Type: Review

References (142)

1. Goel A et al. Curcumin as “Curecumin”: from kitchen to clinic. Biochem Pharmacol 2008; 75: 787–809.
2. Hussain HE. Hypoglycemic, hypolipidemic and antioxidant properties of combination of curcumin from Curcuma longa, Linn. and partially purified product from Abroma augusta, Linn. in streptozotocin induced diabetes. Ind. J Clin Biochem 2002; 17: 33–43.
3. Xu PH et al. The relaxant effect of curcumin on porcine coronary arterial ring segments. Vascul Pharmacol 2007; 47: 25–30.
4. Mukhopadhyay A et al. Anti-inflammatory and irritant activities of curcumin analogues in rats. Agents Actions 1982; 12: 508–515.
5. Moghadamtousi SZ et al. A Review on antibacterial, antiviral, and antifungal activity of curcumin. BioMed Res Int 2014; 2014: 1–12.
6. Gupta SC et al. Therapeutic roles of curcumin: lessons learned from clinical trials. The AAPS J 2013; 15: 195–218.
7. Song K et al. Curcumin suppresses TGF-β signaling by inhibition of TGIF degradation in scleroderma fibroblasts. Biochem Biophys Res Commun 2011; 411: 821–825.
8. Kalaiarasi R et al. A rapid biological synthesis of silver nanoparticles using leaf broth of Rauvolfia tetraphylla and their promising antibacterial. Indo Am J Pharm Res 2013; 3: 8052–8062.
9. Blecher K et al. The growing role of nanotechnology in combating infectious diseases. Virulence 2011; 2: 395–401.
10. Ghorbani Z et al. Anti-hyperglycemic and insulin sensitizer effects of turmeric and its principle constituent curcumin. Int J Endocrinol Metab 2014; 12: e18081.
11. Mittal BV et al. Hypertension in the developing world: challenges and oppurtunities. Am J Kidney Dis 2010; 55: 590–598.
12. Bhullar KS et al. Curcumin and its carbocyclic analogs: structure-activity in relation to antioxidant and selected biological properties. Molecules 2013; 18: 5389–5404.
13. Chinani WN. Safety and anti-inflammatory activity of curcumin: a component of turmeric (Curcuma longa). J Altern Complement Med 2003; 9: 161–168.
14. Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev 2009; 14: 141–153.
15. Niamsa N, Sittiwet C. Antimicrobial activity of Curcuma longa aqueous extract. J Pharmacol Toxicol 2009; 4: 173–177.
16. Hosny IM et al. Antimicrobial activity of curcumin upon pathogenic microorganisms during manufacture and storage of a novel style cheese ‘Karishcum’. J Am Sci 2011; 7: 611–618.
17. Mun SH et al. Synergistic antibacterial effect of curcumin against methicillin-resistant Staphylococcus aureus. Phytomedicine 2013; 20: 714–718.
18. Dhivya R et al. PH responsive curcumin/ZnO nanocomposite for drug delivery. Adv MaterLett 2015; 6: 505–512.
19. Anand P et al. Bioavailability of curcumin: problems and promises. Mol Pharm 2007; 4: 807–818.
20. Jager R et al. Comparative absorption of curcumin formulations. Nutr J 2014; 13: 11.
21. Priyadarsini KI. Chemical and structural features influencing the biological activity of curcumin. Curr Pharm Des 2013; 19: 2093–2100.
22. Priyadarsini KI. Photophysics, photochemistry and photobiology of curcumin: studies from organic solutions, bio-mimetics and living cells. J Photochem Photobiol 2009; 10: 81–96.
23. Priyadarsini KI. Free radical reactions of curcumin in model membranes. Free Radic Biol Med 1997; 23: 838–884.
24. Sun YM. Theoretical elucidation on the antioxidant mechanism of curcumin: a DFT study. Org Lett 2002; 4: 2909–2911.
25. Mishra B et al. Reactions of superoxide radicals with curcumin: probable mechanisms by optical spectroscopy and EPR. Free Radic Res 2004; 38: 355–362.
26. Abdel Aziz MT et al. The effect of a novel curcumin derivative on pancreatic islet regeneration in experimental type-1 diabetes in rats (long term study). Diabetol Metabol Syndr 2013; 5: 75.
27. Wild S et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047–1053.
28. Pari L et al. Effect of the tetrahydrocurcumin on blood glucose, plasma-insulin and hepatic key enzymes in streptozotocin induced diabetic rats. Basic Clin Physiol Pharmacol 2005; 16: 257–274.
29. Das KK et al. Hypoglycemic activity of curcumin synthetic analogues in alloxan-induced diabetic rats. J Enzyme Inhib Med Chem 2015; 16: 1–7.
30. Pavuluri G et al. Curcumin: the spice for life. Int J Pharm Chem Biol Sci 2011; 1: 48–56.
31. Kundu P et al. Curcumin alleviates matrix metalloproteinase-3 and -9 activities during eradication of Helicobacter pylori infection in cultured cells and mice. PLoS ONE 2011; 6: 1–14.
32. Mohammed NA, Habil NY. Evaluation of antimicrobial activity of curcumin against two oral bacteria. ACIS 2015; 3: 18–21.
33. Mandroli PS, Bhat K. An in-vitro evaluation of antibacterial activity of curcumin against common endodontic bacteria. J Appl Pharm Sci 2013; 3: 106–108.
34. Basniwal RK et al. Curcumin nanoparticles: preparation, characterization, and antimicrobial study. J Agric Food Chem 2011; 59: 2056–2061.
35. Jiang Y et al. Photodynamic action of LED-activated curcumin against Staphylococcus aureus involving intracellular ROS increase and membrane damage. Int J Photoenergy 2014; 2014: 1–8.
36. Chen DY et al. Curcumin inhibits influenza virus infection and haemagglutination activity. Food Chem 2010; 119: 1346–1351.
37. Ya-li LV et al. Activity of curcumin against human cytomegalovirus in vitro. African J Pharm Pharmacol 2012; 6: 30–35.
38. Singh RK et al. Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid. Eur J Med Chem 2010; 45: 1078–1086.
39. Anggakusuma et al. Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells. Gut 2014; 63: 1137–1149.
40. Khalil OAK et al. Curcumin antifungal and antioxidant activities are increased in the presence of ascorbic acid. Food Chem 2012; 133: 1001–1005.
41. Lee W, Lee DG. An antifungal mechanism of curcumin lies in membrane-targeted action within Candida albicans. Int Union of Biochem and Mol Biol 2014; 66: 780–785.
42. Wang Y et al. Study on the antibiotic activity of microcapsule curcumin against foodborne pathogens. Int J Food Microbiol 2009; 136: 71–74.
43. Shanmugam MK et al. The multifaceted role of curcumin in cancer prevention and treatment. Molecules 2015; 20: 2728–2769.
44. Shishodia S et al. Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-kappaB activation through inhibition of IkappaBalpha kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin D1. Carcinogenesis 2003; 24: 1269–1279.
45. Kanai M et al. The Potential Role of Curcumin for Treatment of Pancreatic Cancer. In: Sanjay S, ed. Pancreatic Cancer - Molecular Mechanism and Targets, Intech, Europe/China, 2012: 213–224.
46. Singh S, Aggarwal BB. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane). J Biol Chem 1995; 270: 24995–25000.
47. Patel BB et al. Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R. Anticancer Res 2010; 30: 319–325.
48. Xie M et al. Nano-curcumin prepared via supercritical: Improved anti-bacterial, anti-oxidant and anti-cancer efficacy. Int J Pharm 2015; 496: 732–740.
49. Basniwal RK et al. Improving the anticancer activity of curcumin using nanocurcumin dispersion in water. Nutr Cancer 2014; 66: 1015–1022.
50. Shimokawa H, Matoba T. Hydrogen peroxide as an endothelium-derived hyperpolarizing factor”. Pharmacol Res 2004; 49: 543–549.
51. Kajiya M. Impaired NO-mediated vasodilation with increased superoxide but robust EDHF function in right ventricular arterial microvessels of pulmonary hypertensive rats. Am J Physiol 2007; 292: 2737–2744.
52. Kolluru GK et al. Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing. Int J Vasc Med 2012; 2012: 1–30.
53. Yu W et al. Curcumin protects neonatal rat cardiomyocytes against high glucose-induced apoptosis via PI3K/Akt signalling pathway. J Diabetes Res 2016; 2016: 1–11.
54. Soetikno V et al. Curcumin prevents diabetic cardiomyopathy in streptozotocin-induced diabetic rats: possible involvement of PKC-MAPK signaling pathway. Eur J Pharm Sci 2012; 47: 604–614.
55. Feng B et al. Regulation of cardiomyocyte hypertrophy in diabetes at the transcriptional level. Am J Physiol 2008; 294: E1119–E1126.
56. Wongeakin N et al. Molecular mechanisms of curcumin on diabetes-induced endothelial dysfunctions: Txnip, ICAM-1, and NOX2 Expressions. BioMed Research Int 2014; 2014: 1–10.
57. Rungseesantivanon S et al. Curcumin supplementation could improve diabetes-induced endothelial dysfunction associated with decreased vascular superoxide production and PKC inhibition. BMC Complementary and Altern Med 2010; 10: 57.
58. Singh N et al. Insulin catalyzes the curcumin-induced wound healing: an in vitro model for gingival repair. Indian J Pharmacol 2012; 44: 458–462.
59. Rungseesantivanon S et al. “Curcumin improves prostanoid ratio in diabetic mesenteric arteries associated with cyclooxygenase-2 and NF-ƙB suppression”, Diabetes. Metab Syndr Obes: Targets Ther 2010; 3: 421–429.
60. Kumar PA et al. Modulation of α-crystallin chaperone activity in diabetic rat lens by curcumin. Mol Vision 2005; 11: 561–568.
61. Kumar PA et al. Elevated expression of αA- and αB-crystallins in streptozotocin-induced diabetic rat. Arch Biochem Biophys 2005; 444: 77–83.
62. Premanand C et al. Effect of curcumin on proliferation of human retinal endothelial cells under in vitro conditions. Invest Ophthalmol Visual Sci 2006; 47: 2179–2184.
63. Ma QL et al. β-Amyloid oligomers induce phosphorylation of Tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci 2009; 29: 9078–9089.
64. Li Y et al. Curcumin attenuates diabetic neuropathic pain by downregulating TNF-α in a rat model. Int J Med Sci 2013; 10: 377–381.
65. Lee AY, Chung SS. Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB J 1999; 13: 23–30.
66. Cheng HM, Gonzalez RG. The effect of high glucose and oxidative stress on lens metabolism, aldose reductase, and senile cataractogenesis. Metab, Clin Exp 1986; 35: 10–14.
67. Vincent AM et al. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev 2004; 25: 612–628.
68. Grama CN et al. Efficacy of biodegradable curcumin nanoparticles in delaying cataract in diabetic rat model. PLoS ONE 2013; 8: e78217.
69. Joshi RP et al. SNEDDS curcumin formulation leads to enhanced protection from pain and functional deficits associated with diabetic neuropathy: an insight into its mechanism for neuroprotection. Nanomed J 2013; 9: 776–785.
70. Mima A et al. Inflammation and oxidative stress in diabetic nephropathy: new insights on its inhibition as new therapeutic targets. J Diabetes Res 2013; 2013: 1–8.
71. Sharma V, Sharma PL. Role of different molecular pathways in the development of diabetes-induced nephropathy. J Diabetes Metab 2013; S9: 004.
72. Soetikno V. Role of Protein Kinase c-MAPK, oxidative stress and inflammation pathways in diabetic nephropathy. J Nephrol Therapeutic 2012; S2: 001.
73. Olgemoller B, Schleicher E. Alterations of glomerular matrix proteins in the pathogenesis of diabetic nephropathy. Clin Investig 1993; 71: S13–S19.
74. Kolset SO et al. Diabetic nephropathy and extracellular matrix. J of Histochem and Cytochem 2012; 60: 976–986.
75. Soetikno V et al. Curcumin attenuates diabetic nephropathy by inhibiting PKC-α and PKC-β1 activity in streptozotocin-induced type I diabetic rats. Mol Nutr Food Res 2011; 55: 1655–1665.
76. Li R et al. Curcumin inhibits transforming growth factor-β1-induced EMT via PPARγ pathway, not smad pathway in renal tubular epithelial cells. PLoS ONE 2013; 8: e58848.
77. Soetikno V et al. Curcumin alleviates oxidative stress, inflammation, and renal fibrosis in remnant kidney through the Nrf2–keap1 pathway. Mol Nutr Food Res 2013; 57: 1649–1659.
78. Schena FP, Gesualdo L. Pathogenetic mechanisms of diabetic nephropathy. J Am Soc Nephrol 2005; 16: 30–33.
79. Farhangkhoee H et al. Differential effects of curcumin on vasoactive factors in the diabetic rat heart. Nutr Metab 2006; 3: 27–34.
80. Sharma S et al. Curcumin, the active principle of turmeric (Curcuma longa), ameliorates diabetic nephropathy in rats. Clin Exp Pharmacol Physiol 2006; 33: 940–945.
81. Kaur H et al. Diabetes induced extracellular matrix protein expression is mediated by transcription coactivator p300. Diabetes 2006; 55: 3104–3111.
82. Bader MS. Diabetic foot infection. Am Fam Physician 2008; 78: 71–79.
83. Ungphaiboon S et al. Study on antioxidant and antimicrobial activities of turmeric clear liquid soap for wound treatment of HIV patients. Songklanakarin J Sci Technol 2005; 27: 269–578.
84. Gandhi P et al. Soluble curcumin: a promising oral supplement for health management. J Appl Pharm Sci 2011; 2011: 01–07.
85. Charitra GN et al. Efficacy of biodegradable curcumin nanoparticles in delaying cataract in diabetic rat model. PLoS ONE 2013; 8: 01–08.
86. Sidhu GS et al. Enhancement of wound healing by curcumin in animals. Wound Repair Regen 1998; 6: 167–177.
87. Chereddy KK et al. Combined effect of PLGA and curcumin on wound healing activity. J Controlled Release 2013; 171: 208–215.
88. Balasuriya BWN, Rupasinghe HPV. Plant flavonoids as angiotensin converting enzyme inhibitors in regulation of hypertension. Functional Foods Health and Dis 2011; 5: 172–188.
89. Kang DG et al. Hypotensive effect of butein via inhibition of angiotensin converting enzyme. Biol Pharm Bull 2003; 26: 1345–1347.
90. Loizzo MR et al. Inhibition of angiotensin converting enzyme (ACE) by flavonoids isolated from Ailanthus excelsa (Roxb) (Simaroubaceae). Phytother Res 2007; 21: 32–36.
91. Baynes JW. Thorpe SR “Role of oxidative stress in diabetic complications: a new perspective on an old paradigm”. Diabetes 1999; 48: 1–9.
92. Dandona P et al. Oxidative damage to DNA in diabetes mellitus. Lancet 1996; 347: 444–445.
93. Sakurai T et al. Superoxide production from nonenzymatically glycated protein. FEBS Lett 1988; 236: 406–410.
94. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813–820.
95. Mohazzab HKM et al. NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium. Am J Physiol 1994; 266: 2568–2572.
96. Smith CJ et al. Upregulation of inducible nitric oxide synthase contributes to attenuated cutaneous vasodilation in essential hypertensive humans. J Am Heart Assoc 2011; 8: 935–942.
97. Hlavačková L et al. Spice up the hypertension diet - curcumin and piperine prevent remodeling of aorta in experimental L-NAME induced hypertension. Nutr Metab 2011; 8: 72.
98. Palei AC et al. Role of nitric oxide on blood pressure regulation in pregnant rats on a high-fat diet (HFD). Pregnancy Hypertens 2015; 5: 7.
99. Vallance P et al. (1989) Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989; 2: 997–1000.
100. Pacher P et al. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007; 87: 315–424.
101. Gryglewski RJ et al. Superoxide anion is involved in the breakdown of endothelium derived vascular relaxing factor. Nature 1986; 320: 454–456.
102. Oraya K et al. Effect of curcumin and its analogs on rat pulmonary artery. Open Conf Proc J 2013; 4: 87.
103. Nakmareong S et al. Antioxidant and vascular protective effects of curcumin and tetrahydrocurcumin in rats with L-NAME-induced hypertension. Naunyn Schmiedebergs Arch Pharmacol 2011; 383: 519–529.
104. Haefliger JA et al. Aortic connexin43 is decreased during hypertension induced by inhibition of nitric oxide synthase. Arterioscler Thromb Vasc Biol 1999; 19: 1615–1622.
105. Houston MC. The role of mercury and cadmium heavy metals in vascular disease, hypertension, coronary heart disease, and myocardial infarction. Altern Ther Health Med 2007; 13: 128–133.
106. Satarug S et al. Cadmium-induced nephropathy in the development of high blood pressure. Toxicol Lett 2005; 157: 57–68.
107. Eum KD et al. Cadmium in blood and hypertension. Sci Total Environ 2008; 407: 147–153.
108. Lee BK, Kim Y. Association of blood cadmium with hypertension in the Korean general population: analysis of the 2008–2010 Korean national health and nutrition examination survey data. Am J Ind Med 2012; 55: 1060–1067.
109. Lee MS et al. Cadmium exposure and cardiovascular disease in the 2005 Korean national health and nutrition examination survey. Environ Res 2011; 111: 171–176.
110. Obioha UE et al. Hepatoprotective potentials of onion and garlic extracts on cadmium-induced oxidative damage in rats. Biol Trace Elem Res 2009; 129: 143–156.
111. Roels HA et al. Usefulness of biomarkers of exposure to inorganic mercury, lead, or cadmium in controlling occupational and environmental risks of nephrotoxicity. Ren Fail 1999; 21: 251–262.
112. Revis N. A possible mechanism for cadmium-induced hypertension in rats. Life Sci 1978; 22: 479–487.
113. Skoczynska A, Martynowicz H. The impact of subchronic cadmium poisoning on the vascular effect of nitric oxide in rats. Hum Exp Toxicol 2005; 24: 353–361.
114. Prozialeck WC et al. The vascular system as a target of metal toxicity. Toxicol Sci 2008; 102: 207–218.
115. Kukongviriyapan U et al. Curcumin protects against cadmium-induced vascular dysfunction, hypertension and tissue cadmium accumulation in mice. Nutrients 2014; 6: 1194–1208.
116. Tiwari SK et al. Curcumin-loaded nanoparticles potently induce adult neurogenesis and reverse cognitive deficits in Alzheimer's disease model via canonical Wnt/β-catenin pathway. ACS Nano 2014; 8: 76–103.
117. Xie X et al. PLGA nanoparticles improve the oral bioavailability of curcumin in rats: characterizations and mechanisms. J Agric Food Chem 2011; 59: 9280–9289.
118. Bhattacharyya S et al. Tumor-induced oxidative stress perturbs nuclear factor-kappaB activity-augmenting tumor necrosis factor-alpha-mediated T-cell death: protection by curcumin. Cancer Res 2007; 67: 362–370.
119. Makarov VV et al. “Green” nanotechnologies: synthesis of metal nanoparticles using plants. Acta Naturae 2014; 6: 35–44.
120. Iravani S. Green synthesis of metal nanoparticles using plants. Green Chem 2011; 13: 2638–2650.
121. Umrani RD, Paknikar KM. Zinc oxide nanoparticles show antidiabetic activity in streptozotocin-induced Type 1 and 2 diabetic rats. Nanomed 2014; 9: 89–104.
122. Taccola L et al. Zinc oxide nanoparticles as selective killers of proliferating cells. Int J Nanomed 2011; 6: 1129–1140.
123. Kim YR et al. Toxicity of 100 nm zinc oxide nanoparticles: a report of 90-day repeated oral administration in Sprague Dawley rats. Int J Nanomed 2014; 9: 109–126.
124. Yallapu MM et al. Novel curcumin-loaded magnetic nanoparticles for pancreatic cancer treatment. Mol Cancer Ther 2013; 12: 1471–1480.
125. Sun D et al. A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol Ther 2010; 18: 1606–1614.
126. Dilnawaz F et al. Transferrin-conjugated curcumin-loaded superparamagnetic iron oxide nanoparticles induce augmented cellular uptake and apoptosis in K562 cells. Acta Biomater 2012; 8: 704–719.
127. Wang W et al. Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles. Int J Nanomed 2012; 7: 3667–3677.
128. Bisht S et al. Polymeric nanoparticle-encapsulated curcumin (“nanocurcumin”): a novel strategy for human cancer therapy. J Nanobiotech 2007; 5: 3.
129. Cheng KK et al. Highly stabilized curcumin nanoparticles tested in an in vitro blood–brain barrier model and in Alzheimer's Disease Tg2576 Mice. The AAPS J 2013; 15: 324–336.
130. Mishra S, Palanivelu K. The effect of curcumin (turmeric) on Alzheimer's disease: an overview. Ann Indian Acad Neurol 2008; 11: 13–19.
131. Chen Y et al. Preparation of curcumin-loaded liposomes and evaluation of their skin permeation and pharmacodynamics. Molecules 2012; 17: 5972–5987.
132. Sonavane K et al. Topical curcumin-based cream is equivalent to dietary curcumin in a skin cancer model”. J Skin Cancer 2012; 2012: 147863.
133. Mulik RS et al. Transferrin mediated solid lipid nanoparticles containing curcumin: enhanced in vitro anticancer activity by induction of apoptosis. Int J Pharm 2010; 398: 190–203.
134. Gonçalves C et al. Self-assembled dextrin nanogel as curcumin delivery system. J Biomater Nanobiotechnol 2012; 3: 178–184.
135. Falconieri MC et al. New dendrimer-based nanoparticles enhance curcumin solubility. Planta Med 2016; eFirst. doi:10.1055/s-0042-103161.
136. Some S et al. Cancer therapy using ultrahigh hydrophobic drug-loaded graphene derivatives. Sci Rep 2014; 4: 6314.
137. Sawant VJ et al. PEG-cyclodextrin coated curcumin loaded zinc ferrite core nanocomposites as pH-responsive drug delivery system for antiinflammation and anticancer application. Arch Appl Sci Res 2014; 6: 44–54.
138. Rahman M et al. Classical to current approach for treatment of psoriasis: a review. Endocr Metab Immune Disord: Drug Targets 2012; 12: 287–302.
139. Heng Madalene CY. Use of curcumin in treatment of psoriasis, inflammation, skin wounds, burns, and eczemas. US Patent 5925376, Aug 26, 1999.
140. Yallapu MM et al. Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discovery Today 2012; 17: 71–80.
141. Gabrielli A et al. Scleroderma. N Engl J Med 2009; 360: 1989–2003.
142. Granucci F et al. Nanoconstructs with pharmacological activity. US Patent US 20150224061 A1, Aug 13, 2015.